Reported Earlier, Alkermes Presents First Clinical Data For Orexin 2 Receptor Agonist ALKS 2680 At World Sleep Congress
Portfolio Pulse from Benzinga Newsdesk
Alkermes plc (NASDAQ:ALKS) has announced preliminary results from a phase 1 study evaluating ALKS 2680, a novel orexin 2 receptor agonist in development for the treatment of narcolepsy. The data demonstrated dose-dependent, significantly improved sleep latency compared to placebo in Narcolepsy Type 1. The drug was generally well tolerated at all doses tested. The company plans to initiate a phase 2 study of ALKS 2680 in the first half of 2024.
October 23, 2023 | 2:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alkermes' phase 1 study results for ALKS 2680 show promise, potentially leading to a new treatment for narcolepsy. This could have a positive impact on the company's stock in the short term.
The positive preliminary results from the phase 1 study of ALKS 2680 indicate that the drug is effective and well-tolerated. This could lead to increased investor confidence in Alkermes, potentially driving up the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100